Estrogen replacement therapy (ERT) is a type of hormone replacement therapy which is used for the treatment or reduction of various symptoms caused as a result of menopause. These symptoms consist of hot flashes, irregular sleeping patterns and vaginal dryness. Menopause is the stage in every woman’s life where the body begins to slow down the production of hormones, including estrogen and progesterone. This can result in development of disorders such as osteoporosis as well. Estrogen can be used in combination with progestin in order to provide better treatment and reduce the risk of some major side effects.
As per the National Health Service in UK, the menopause usually occurs between the age of 45 and 55 years. The average age for a woman to reach menopause in the United Kingdom is 51 after which the estrogen levels begin to decrease in the body. However, it was reported that about 1 in every 100 women experience menopause before the age of 40 years, which is known as premature menopause or premature ovarian insufficiency. As a result of this, the number of women going through the menopause is predicted to increase at a high rate, thereby raising the demand for estrogen replacement therapy. The estrogen replacement therapy market is anticipated to record a significant CAGR over the forecast period, i.e., 2020-2028. The market is segmented by route of administration and by region. On the basis of route of administration, the market is segmented into oral, topical, transdermal, vaginal and parenteral, out of which, the oral segment is anticipated to hold the largest share in the estrogen replacement therapy market on account of ease of administration of estrogen in the oral forms such as tablets and capsules. Bijuva, an estrogen and progesterone therapy manufactured by TherapeuticsMD, Inc., received FDA approval in 2018.The therapy is for oral use in the form of capsules and is recommended to be taken one daily.
According to a report published by the Centers for Disease Control and Prevention in 2017, around 27.1% of postmenopausal women between the ages 40 and 59 were highly likely to have trouble falling asleep as compared with premenopausal women. Moreover, about 55.1% of postmenopausal women aged between 40 and 59 were more likely than premenopausal women to wake up not feeling well rested for at least 4 days per week. Growing awareness among women about the serious implications of menopause which can lead to disorders and discomfort and affect their daily lives has resulted in the increasing adoption of hormone therapies such as estrogen replacement therapy by women. This is anticipated to lead to substantial market growth during the forecast period. CLICK TO DOWNLOAD SAMPLE REPORT
The rising population of post-menopausal women is attributed to the growing demand for improved estrogen replacement therapies with better efficacy and lesser side-effects. Further, the benefits of estrogen therapy in improving health conditions such as osteoporosis are estimated to increase the demand in near future. On account of these factors, the market growth is anticipated to witness a notable hike over the forecast period.
Medications containing hormones show certain side-effects which might be either mild or serious. Moreover, estrogen replacement therapy cannot be used in case women have the conditions such as liver problems, bleeding disorder, pregnancy, severe reactions to estrogen medicines among other health conditions. This is estimated to hamper the market growth in the next few years.
Our in-depth analysis of the estrogen replacement therapy market includes the following segments:
On the basis of regional analysis, the estrogen replacement therapy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
Estrogen replacement market in North America is anticipated to hold the largest share in the market on account of rising number of older women undergoing the menopause, which is increasing the demand for estrogen therapy in order to provide comfort and make daily life easier. The market in Europe is projected to hold a significant share in the market as well owing to advancements in technology in the healthcare industry which is resulting in development of new and improved estrogen replacement therapies with lesser side effects.
The estrogen replacement therapy market is further classified on the basis of region as follows:
FREQUENTLY ASKED QUESTIONS
Rising awareness among women about the serious implications of menopause which can lead to disorders and discomfort is a major growth factor for the market growth.
The market is anticipated to attain a significant CAGR over the forecast period, i.e. 2020-2028.
The market in Europe is anticipated to provide increased business opportunities as a result of growing technological advancements in the healthcare industry.
The major players in the market are Abbott Laboratories, Pfizer Inc., Novartis, Bayer Healthcare, Eli Lilly, Novo Nordisk, Merck, Allergan, Orion Pharma and TherapeuticsMD, Inc.
Company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization